Literature DB >> 25661444

Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Julie Mondet1, Ji-Hye Park2, Audrey Menard3, Christophe Marzac4, Serge Carillo5, Emmanuel Pourcelot6, Francois Girodon7, Xenia Cabagnols8, Laurence Lodé9, Nuria Socoro6, Martine Chauvet10, Claude-Eric Bulabois11, Pascale Cony-Makhoul12, Selim Corm13, Jean-Yves Cahn14, Pascal Mossuz6.   

Abstract

Entities:  

Keywords:  calreticulin mutations; endogenous megakaryocytic colonies; essential thrombocythemia; megakaryocytes

Mesh：

Substances：

Year:  2015        PMID： 25661444      PMCID： PMC4420225          DOI： 10.3324/haematol.2014.118927

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia.

Authors:  Irène Dobo; Nathalie Boiret; Eric Lippert; François Girodon; Pascal Mossuz; Magali Donnard; Lydia Campos; Danielle Pineau; Elisabeth Bascans; Vincent Praloran; Sylvie Hermouet
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

2.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Authors:  Eric Lippert; Marjorie Boissinot; Robert Kralovics; François Girodon; Irène Dobo; Vincent Praloran; Nathalie Boiret-Dupré; Radek C Skoda; Sylvie Hermouet
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.

Authors:  Marjorie Boissinot; Eric Lippert; Francois Girodon; Irene Dobo; Marc Fouassier; Claude Masliah; Vincent Praloran; Sylvie Hermouet
Journal:  Blood       Date:  2006-11-01       Impact factor: 22.113

4.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  Endogenous megakaryocytic colony formation and thrombopoietin sensitivity of megakaryocytic progenitor cells are useful to distinguish between essential thrombocythemia and reactive thrombocytosis.

Authors:  J Q Mi; F Blanc-Jouvan; J Wang; M F Sotto; F Cousin; A Castinel; M Chauvet; J J Sotto; B Polack; P Mossuz
Journal:  J Hematother Stem Cell Res       Date:  2001-06

6.  Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

Authors:  Elaine M Boyd; Anthony J Bench; Andrea Goday-Fernández; Shubha Anand; Krishna J Vaghela; Phillip Beer; Mike A Scott; David Bareford; Anthony R Green; Brian Huntly; Wendy N Erber
Journal:  Br J Haematol       Date:  2010-02-11       Impact factor: 6.998

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  Presence of calreticulin mutations in JAK2-negative polycythemia vera.

Authors:  Julien Broséus; Ji-Hye Park; Serge Carillo; Sylvie Hermouet; François Girodon
Journal:  Blood       Date:  2014-10-10       Impact factor: 22.113

9.  In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.

Authors:  Alessandra Balduini; Stefania Badalucco; Maria Teresa Pugliano; Denis Baev; Annalisa De Silvestri; Marco Cattaneo; Vittorio Rosti; Giovanni Barosi
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

10.  Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.

Authors:  A M Vannucchi; G Rotunno; N Bartalucci; G Raugei; V Carrai; M Balliu; C Mannarelli; A Pacilli; L Calabresi; R Fjerza; L Pieri; A Bosi; R Manfredini; P Guglielmelli
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528
View more
  4 in total

Review 1.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 2.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Misa Imai; Marito Araki; Norio Komatsu
Journal:  Int J Hematol       Date:  2017-05-03       Impact factor: 2.490

3.  Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms.

Authors:  William Vainchenker; Isabelle Plo; Mira El-Khoury; Xénia Cabagnols; Matthieu Mosca; Gaëlle Vertenoeil; Christophe Marzac; Fabrizia Favale; Olivier Bluteau; Florence Lorre; Amandine Tisserand; Graciela Rabadan Moraes; Valérie Ugo; Jean-Christophe Ianotto; Jerôme Rey; Eric Solary; Lydia Roy; Philippe Rameau; Najet Debili; Florence Pasquier; Nicole Casadevall; Caroline Marty; Stefan N Constantinescu; Hana Raslova
Journal:  Oncogene       Date:  2020-06-22       Impact factor: 9.867

Review 4.  Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.

Authors:  Marito Araki; Norio Komatsu
Journal:  Cancer Sci       Date:  2017-08-08       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.